Literature DB >> 30950971

PHOTODYNAMIC THERAPY FOR EXTRAFOVEOLAR CHOROIDAL OSTEOMA.

Mehdi Mazloumi1, Lauren A Dalvin1,2, David Ancona-Lezama1, Arman Mashayekhi1, Carol L Shields1.   

Abstract

PURPOSE: To evaluate the outcome of photodynamic therapy (PDT) in the management of extrafoveolar choroidal osteoma.
METHODS: The authors performed a retrospective chart review of all patients with choroidal osteoma that did not involve the foveola and were treated with standard-fluence PDT.
RESULTS: Nine eyes with extrafoveolar choroidal osteoma were studied. Mean logarithm of the minimum angle of resolution best-corrected visual acuity at initial examination was 0.07 (Snellen ∼20/25). The osteoma was treated with 1 (8/9) or 2 (1/9) PDT sessions using 50 J/cm. After a mean follow-up of 49 months, the treated area of osteoma demonstrated complete (4/9) or partial (5/9) regression, with a mean of 73% regression in the PDT-treated areas. Tumor growth in the region of PDT was noted in 3 cases (3/9) (one tumor toward the foveola and two tumors at the margin away from the foveola), but in no case did the tumor reach the foveola. Therefore, PDT controlled tumor growth in 8 of 9 cases with only 1 of 9 cases showing growth through the PDT scar into foveola. Mean logarithm of the minimum angle of resolution visual acuity at last follow-up was 0.04 (Snellen ∼20/20) (P = 0.59).
CONCLUSION: Photodynamic therapy is an effective modality for the management of extrafoveolar choroidal osteoma, minimizing tumor growth toward the foveola and preserving visual acuity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 30950971     DOI: 10.1097/IAE.0000000000002534

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  2 in total

1.  Intravitreally injected ranibizumab versus photodynamic therapy for CNV secondary to choroidal osteoma: a 7-year follow-up case report.

Authors:  Li-Yuan Rong; Li Ran; Shi-Ying Li; Xiao-Hong Meng; Yan-Ling Long; Hai-Wei Xu
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

2.  Secondary choroidal neovascularization due to choroidal osteoma after 9 years follow-up.

Authors:  Yun Zhang; Jia Fang; Shixin Zhao; Xiangjun She; Jun Wang; Lijun Shen
Journal:  BMC Ophthalmol       Date:  2021-05-31       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.